Clinically important immune-mediated hematologic adverse reactions (including hemolytic anemia, aplastic anemia, immune thrombocytopenic purpura) transpired at an incidence of fewer than 1% in patients who been given this drug or had been described with using other PD-one/PD-L1 blocking antibodies.